Summary: “Oncology ICD-10 codes are the ICD-10-CM Chapter 2 neoplasm codes, spanning C00 through D49, used to report cancer diagnoses on claims. Behavior is signaled by the code itself — C codes report malignant neoplasms, while D codes report in situ, benign, uncertain, and unspecified neoplasms. The chapter organizes codes by anatomic site first, then by tumor behavior. Key documentation requirements include primary site, laterality, behavior, metastatic sites, and treatment phase. Z codes (Z51.11, Z51.12, Z51.0, Z85) support encounter coding for chemotherapy, immunotherapy, radiation, and personal history.”
Oncology ICD-10 codes are the ICD-10-CM Chapter 2 neoplasm codes, spanning C00 through D49, used to report cancer diagnoses on claims. This guide covers four things in order: the behavior categories, the site code ranges, the documentation requirements, and the billing linkage. Behavior is signaled by the code itself, not by a modifier. The first character, C or D, tells you whether a neoplasm is malignant or non-malignant before you read any further.
What Are Oncology ICD-10 Codes?
Oncology ICD-10 codes occupy ICD-10-CM Chapter 2, titled Neoplasms. The chapter range is C00 through D49. The first character and the code itself encode tumor behavior. A neoplasm code identifies the site, the behavior, and laterality, where applicable.
These codes translate a confirmed cancer diagnosis into a standardized form that payers can adjudicate. A single code carries the anatomic site, whether the tumor is malignant or benign, and which side of a paired organ is affected. That density is why neoplasm coding rewards documentation specificity.
The behavior axis follows World Health Organization classification logic. ICD-10-CM, maintained by CMS and the CDC National Center for Health Statistics, applies that logic to United States claims. Coders work from the diagnosis code set, not from the registry system used by tumor registrars.
How Does ICD-10-CM Chapter 2 Classify Neoplasms?
Chapter 2 organizes neoplasms by anatomic site first, then by behavior. The site tells you where the tumor sits. Behavior tells you what the tumor is doing.
The behavior axis has six positions: malignant primary, malignant secondary (metastatic), in situ, benign, uncertain behavior, and unspecified behavior. Two structural choices follow from this. Clinicians can consult an ICD 10 coding guide to verify these structural divisions. The categories below map to the behavior axis.
What Is the Difference Between ICD-10-CM and ICD-O-3?
ICD-10-CM reports the diagnosis on the claim. ICD-O-3 records topography and morphology in cancer registries. The two systems serve different readers and different workflows.
Billers and payers use ICD-10-CM for reimbursement. Registrars use ICD-O-3 to capture histology and tumor morphology for population surveillance. A claim never adjudicates on an ICD-O-3 morphology code.
Is ICD-O-3 Used for Billing Cancer Claims?
No. ICD-O-3 is for registry coding, not claim submission. Payers adjudicate on ICD-10-CM only. The International Classification of Diseases for Oncology, Third Edition, records topography and morphology for cancer registries, while the diagnosis that establishes medical necessity on a claim is always an ICD-10-CM code.
What Are the Categories of Oncology ICD-10 Codes?
Oncology ICD-10 codes fall into six behavior categories: malignant primary, malignant secondary (metastatic), in situ, benign, uncertain behavior, and unspecified behavior. Behavior is read from the code itself, not from a modifier.
| Behavior Category | Code Pattern | Definition | Example Code |
|---|---|---|---|
| Malignant primary | C00-C75, C7A (excl. secondary) | Tumor at the site of origin | C50.911 (malignant neoplasm, right female breast) |
| Malignant secondary (metastatic) | C76-C80, C7B | Spread from a primary site | C78.00 (secondary malignant neoplasm, unspecified lung) |
| In situ | D00-D09 | Confined, non-invasive | D05.11 (intraductal carcinoma in situ, right breast) |
| Benign | D10-D36, D3A | Non-cancerous | D12.6 (benign neoplasm of colon, unspecified) |
| Uncertain behavior | D37-D48 | Pathology cannot determine behavior | D48.5 (neoplasm of uncertain behavior of skin) |
| Unspecified behavior | D49 | Behavior not documented | D49.2 (neoplasm of unspecified behavior, bone, soft tissue, skin) |
The takeaway sits in the first character. A C code reports a malignancy. A D code reports an in situ, benign, uncertain, or unspecified neoplasm. You do not need a modifier to communicate behavior.
What Are Malignant Primary Neoplasm Codes?
Primary malignant codes report the site of origin. A primary malignancy is the tumor at its original anatomic location, before any spread.
These codes dominate the C00-C75 range and account for most of the day-to-day oncology volume. The worked example is C34.90: malignant neoplasm of an unspecified part of an unspecified bronchus or lung. When documentation names the lobe and side, you replace the unspecified characters with the specific ones.
What Are Secondary (Metastatic) Neoplasm Codes?
Secondary codes report the metastatic site, not the origin. They cover a spread from a known or unknown primary tumor.
- C77 reports secondary malignancy of the lymph nodes
- C78 reports secondary malignancy of the respiratory and digestive organs
- C79 reports secondary malignancy of other and unspecified sites
- C7B reports secondary neuroendocrine tumors
A critical sequencing note applies here. When treatment is directed at the metastasis, the secondary code can sequence first, ahead of the primary. The worked example is C78.7, secondary malignant neoplasm of the liver and intrahepatic bile duct. The sequencing rules section below shows when this reversal applies.
What Are In Situ, Benign, and Uncertain-Behavior Codes?
These three behaviors share the D00 through D48 span, and each carries a distinct billing meaning. In situ (D00-D09) means non-invasive and confined. Benign (D10-D36) means non-cancerous. Uncertain behavior (D37-D48) means the tumor could not be classified.
In situ is not “history of” and it is not benign. Mis-mapping any of these three drives denials. An in situ lesion is an active, confined neoplasm that still demands precise coding.
The worked contrast makes the trap concrete. D05.- reports in situ breast carcinoma, a confined lesion. C50.- reports invasive breast cancer. Coding an in situ lesion as benign understates acuity. Coding it as a personal history code removes the active diagnosis entirely.
What Are Neuroendocrine Tumor Codes (C7A, C7B, D3A)?
Neuroendocrine tumor codes sit outside the numeric flow of the chapter. C7A reports malignant neuroendocrine tumors. C7B reports secondary neuroendocrine tumors. D3A reports benign neuroendocrine tumors.
Common sites include the gastrointestinal tract, the pancreas, and the lung. Coders miss these codes because their non-sequential placement breaks the expected C-to-D reading order. Searching by behavior rather than by adjacent code range avoids the oversight.
What Are the Code Ranges in the ICD-10 Neoplasm Chapter (C00-D49)?
The oncology ICD-10 codes are organized into site-based ranges across the full C00 through D49 chapter. The table below maps every range to its body system, which is the single reference most ranking pages fragment across multiple posts.
| Code Range | Body System / Site | Notes |
|---|---|---|
| C00-C14 | Lip, oral cavity, pharynx | Head and neck malignancies |
| C15-C26 | Digestive organs | Esophagus through the anus, liver, pancreas |
| C30-C39 | Respiratory and intrathoracic | Includes bronchus and lung (C34) |
| C40-C41 | Bone and articular cartilage | Primary bone malignancy |
| C43 | Malignant melanoma of the skin | Distinct from other skin (C44) |
| C44 | Other malignant neoplasms of the skin | Basal and squamous cell |
| C45-C49 | Mesothelial and soft tissue | Mesothelioma, sarcoma |
| C50 | Breast | Requires laterality character |
| C51-C58 | Female genital organs | Cervix, ovary, uterus |
| C60-C63 | Male genital organs | Includes prostate (C61) |
| C64-C68 | Urinary tract | Kidney, bladder, ureter |
| C69-C72 | Eye, brain, central nervous system | Includes meninges |
| C73-C75 | Thyroid and other endocrine | Thyroid, adrenal |
| C76-C80 | Ill-defined, secondary, unspecified sites | Includes C80.1 unspecified primary |
| C7A | Malignant neuroendocrine tumors | Non-sequential placement |
| C7B | Secondary neuroendocrine tumors | Metastatic NET |
| C81-C96 | Lymphoid and hematopoietic | Lymphoma, leukemia, myeloma |
| D00-D09 | In situ neoplasms | Confined, non-invasive |
| D10-D36 | Benign neoplasms | Non-cancerous |
| D37-D48 | Uncertain behavior | Pathology cannot classify |
| D3A | Benign neuroendocrine tumors | Non-sequential placement |
| D49 | Unspecified behavior | Behavior not documented |
Which Code Ranges Cover Lymphoid and Hematopoietic Cancers (C81-C96)?
The C81 through C96 block reports blood cancers and is among the most mis-coded ranges. C81 reports Hodgkin lymphoma. C82 through C86 report non-Hodgkin lymphoma. C90 reports plasma cell neoplasms, including multiple myeloma. C91 through C95 report the leukemias.
Many hematologic malignancy codes carry a fifth character for disease status:
- In remission signals that the disease has responded and is currently suppressed
- In relapse signals the disease returned after a remission period
- Not having achieved remission or unspecified status applies when neither is documented
That fifth character changes reimbursement. A leukemia coded “in remission” reads differently to a payer than the same leukemia “in relapse,” so the status must come from the record, not from assumption.
How Do You Document Oncology Diagnoses for ICD-10 Coding?
The record must support site, laterality, behavior, and treatment status before a definitive code is assigned. Code specificity depends on documentation specificity.
A complete oncology note supports each of the following:
- Primary site and histology of the tumor
- Behavior: primary, secondary, in situ, or benign
- Laterality: right, left, or bilateral for paired organs
- Metastatic sites, if any are present
- Treatment phase: active, post-treatment, or in remission
- Pathology and staging reference confirming the diagnosis
Unspecified codes, such as C80.1, signal under-documentation and invite payer scrutiny. A code like C80.1, malignant neoplasm of unspecified primary site, should appear only when the primary truly cannot be identified, not as a shortcut around a thin note.
How Do Laterality and Anatomic Site Drive Code Selection?
Paired-site cancers, including breast, lung, kidney, and ovary, require a laterality character. The code is invalid without it.
The breast example shows the rule in action. C50.911 reports a malignant neoplasm of the right female breast. C50.912 reports the left. A claim that omits laterality on a paired-organ malignancy submits an invalid or unspecified code, which carries direct denial risk.
Does Oncology Coding Require Pathology Confirmation?
Generally, yes for definitive malignancy coding. Definitive neoplasm codes require provider documentation of a confirmed diagnosis. Without confirmed pathology, code the signs, symptoms, or suspected behavior rather than a definitive malignancy. Assigning a confirmed cancer code to a suspected diagnosis overstates the clinical picture and exposes the claim to audit and recoupment.
How Are Oncology ICD-10 Codes Used in Medical Billing?
The ICD-10 code establishes the medical necessity that justifies the CPT or HCPCS service billed. ICD-10 reports why care was given. CPT and HCPCS report what was done.
Every cancer claim pairs a diagnosis with a procedure. The diagnosis pointer links the ICD-10 code to the specific service line, telling the payer that the documented malignancy justifies the chemotherapy administration, the radiation session, or the surgical procedure billed. Local Coverage Determinations (LCD) and National Coverage Determinations (NCD) define which diagnoses support which services.
Payer edits sit on top of that linkage. The CCI and MUE edits screen for unbundling and impossible unit counts. J-codes report the chemotherapy drugs themselves. When the diagnosis-to-procedure link fails an LCD or NCD policy, the line is denied for medical necessity. Practices that want this linkage managed end-to-end can route it to oncology medical billing services.
How Do ICD-10 Codes Link to CPT and HCPCS for Cancer Care?
A chemotherapy administration CPT code, such as 96413, is paired with the malignancy ICD-10 code and a Z51.1x encounter code. That pairing forms the diagnosis-procedure-drug triad on the claim. Practices can check current CPT codes for Oncology billing to match procedural lines with drug codes.
The triad reads as one statement of medical necessity:
| Claim Element | Code Type | Example | Role |
|---|---|---|---|
| Encounter reason | ICD-10 Z code | Z51.11 | Why the patient presented |
| Diagnosis | ICD-10 C code | C50.911 | The condition treated |
| Service | CPT | 96413 | The chemotherapy administered |
| Drug | HCPCS J-code | J-code for the agent | The substance infused |
Is ICD-10 the Same as CPT for Cancer Billing?
No. ICD-10 codes report the diagnosis and establish medical necessity. CPT and HCPCS codes report the service performed. Both appear on the same claim and must align with each other. A chemotherapy CPT code without a supporting malignancy diagnosis fails the medical-necessity test and is denied, even when the service was clinically appropriate.
What Z Codes Support Oncology Encounters?
Z codes report the reason for an oncology encounter when the visit is not for a new diagnosis. Z51.1x codes report the encounter reason when a patient presents for cancer treatment.
| Z Code | Meaning | When Used |
|---|---|---|
| Z51.11 | Encounter for antineoplastic chemotherapy | Patient presents for a chemo session |
| Z51.12 | Encounter for antineoplastic immunotherapy | Patient presents for immunotherapy |
| Z51.0 | Encounter for antineoplastic radiation therapy | Patient presents for radiation |
| Z85.- | Personal history of malignant neoplasm | Cancer eradicated, no current treatment |
| Z08 | Follow-up exam after completing the malignancy treatment | Surveillance after treatment ends |
| Z80.- | Family history of primary malignancy | Risk and screening justification |
| Z12.- | Encounter for screening for malignant neoplasm | Screening before any diagnosis |
| Z17.0 / Z17.1 | Estrogen receptor positive/negative status | Receptor status reporting (progesterone is Z17.2-) |
| Z92.21 | Personal history of antineoplastic chemotherapy | Prior chemo history relevant to current care |
A note on Z17: Z17.0 and Z17.1 report estrogen receptor status only, positive and negative. Progesterone receptor status uses Z17.2-, and HER2 status uses Z17.3-. Use one code per receptor when the pathology report documents them.
How Do You Code Chemotherapy and Immunotherapy Encounters?
When a patient presents for chemotherapy, sequence Z51.11 first, then the malignancy code. The same pattern applies to Z51.12 for immunotherapy and Z51.0 for radiation therapy.
This sequencing reverses when the admission is for the malignancy itself rather than for the treatment encounter. The worked example for a treatment visit is Z51.11 followed by C50.911. The sequencing rules section below sets out the full decision logic.
How Do You Code Personal and Family History of Cancer?
Z85.- reports a personal history of malignancy after eradication, with no current treatment and no recurrence. It marks a patient who has completed treatment and shows no active disease. An active malignancy still uses a C code.
The contrast and the trap both matter:
- Active disease uses the C code for the malignant site.
- Personal history uses Z85- only after eradication with no current treatment.
- Family history uses Z80 to justify screening and risk assessment.
Coding personal history while a patient is still in active treatment understates clinical acuity. That mismatch triggers denials and undercuts the medical-necessity case for ongoing therapy.
How Do Sequencing Rules Work in Oncology ICD-10 Coding?
The reason for the encounter determines sequencing. Identify why the patient presented, then order the codes to match that reason. The decision table below covers the four recurring scenarios.
| Scenario | Sequence First | Then |
|---|---|---|
| Encounter for chemo, radiation, or immunotherapy | Z51.x encounter code | Malignancy code |
| Admission or encounter to treat the malignancy | Malignancy code | Any complications |
| Treatment directed at the metastasis | Secondary code (C77-C79) | Primary malignancy |
| Malignancy eradicated, no treatment, no recurrence | Z85.- history | No active C code |
These rules follow the ICD-10-CM Official Guidelines for Coding and Reporting, Section I.C.2, published by CMS and the CDC. The encounter reason is the controlling fact in every row. A patient who arrives for a chemo session and a patient admitted to treat the tumor receive the same diagnosis in a different order.
Can a Cancer Be Coded as Active After Treatment Ends?
Only while the disease is present or under active treatment. Active malignancy coding stops when treatment ends, and no disease remains. Once the cancer is eradicated, with no recurrence and no ongoing treatment, switch from the C code to the Z85- personal history code. Reporting an active malignancy after that point overstates acuity and misrepresents the patient’s current status to the payer.
How Do You Code an Oncology Encounter Step by Step?
Coding an oncology encounter follows a fixed order that resolves behavior, site, and sequencing before the claim is built. Work the steps in sequence.
- Confirm the pathology, diagnosis, and tumor behavior from the record.
- Identify the primary site and its laterality.
- Identify any secondary or metastatic sites.
- Determine the encounter reason: treatment, evaluation, or follow-up.
- Select the malignancy code or codes to the highest available specificity.
- Add Z51.x, Z85, or Z08 as the encounter scenario requires.
- Apply the sequencing rule for that encounter reason.
- Link the diagnosis to the CPT or HCPCS service and verify against LCD and NCD policy.
What Are Common Oncology ICD-10 Coding and Denial Errors?
Specificity and sequencing errors drive most oncology claim denials. Each error below maps to a predictable claim consequence and, where it fits, a payer adjustment code.
- Using an unspecified site code (C80.1) when the site is documented leads to a medical-necessity denial, often CARC CO-50.
- Missing laterality on a paired-organ cancer produces an invalid code and a CO-16 missing-information rejection.
- Coding personal history (Z85) during active treatment understates acuity and weakens the necessity case.
- Wrong sequencing of Z51.x against the malignancy triggers a claim edit and rework.
- Coding an in situ lesion as benign or as history produces incorrect reimbursement.
- Omitting the metastatic site under-codes the encounter and undervalues the service.
Frequently Asked Questions About Oncology ICD-10 Codes
What ICD-10 chapter covers cancer?
Cancer is reported in ICD-10-CM Chapter 2, Neoplasms, which spans C00 through D49. C codes report malignant neoplasms. D codes report in situ, benign, uncertain, and unspecified neoplasms. The chapter organizes codes by anatomic site first, then by tumor behavior.
How do you code metastatic cancer?
Metastatic cancer uses both a primary malignancy code and a secondary code from the C77 through C79 range. Sequencing follows the encounter reason. When treatment targets the metastasis, the secondary site code sequences first, ahead of the primary tumor code.
What is the ICD-10 code for chemotherapy?
The encounter code for chemotherapy is Z51.11, an encounter for antineoplastic chemotherapy. It reports why the patient presented and sequences first on a treatment visit. The malignancy code follows it. Z51.12 covers immunotherapy, and Z51.0 covers radiation therapy.
What is the difference between C and D codes?
C codes report malignant neoplasms, both primary and secondary. D codes report in situ, benign, uncertain-behavior, and unspecified-behavior neoplasms. The first character communicates behavior directly, so no modifier is needed to signal whether a tumor is cancerous.
When do you use Z85?
Use Z85.- for a personal history of malignant neoplasm after the cancer is eradicated, with no current treatment and no recurrence. While the patient remains in active treatment or carries active disease, code the malignancy with its C code instead.
